AmEx Pharmacy Recalls Bevacizumab 1.25mg/0.05mL 31G Injectable
The company is voluntarily recalling the product due to difficulties with the delivery system.
The company is voluntarily recalling the product due to difficulties with the delivery system.
AmEx Pharmacy announced on April 29, 2019 that it was voluntarily recalling one lot of Bevacizumab 1.25mg/0.05mL 31G Injectable because the Monoject Syringe may require additional force to express the drug. This additional force could cause injury to the eye, the company stated in a press release. Bevacizumab 1.25mg/0.05mL 31G Injectable is used to treat wet age-related macular degeneration and diabetic retinopathy.
The recalled product is individually wrapped, labeled in a Tyvek pouch, and contained in a labeled amber bag. The recalled lot, 190212AB, BUD 5/13/2019, was distributed nationwide to ophthalmologist clinics in Arizona, Illinois, Indiana, Kansas, Pennsylvania, Tennessee, Texas, and Wisconsin.
AmEx Pharmacy has received three reports associated with the recalled lot, two of which resulted in an adverse event. Adverse events may be reported to FDA via its MedWatch program.
Source: FDA
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
